Association between -592C＞A polymorphism within gene promoter region of interleukin-10 and susceptibility of cervical cancer: a meta-analysis
GUO Chong1 ZHANG Zhijun2
1.Department of Obstetrics and Gynecology, Taihe Hospital of Shiyan City, Hubei Province, Shiyan 442000, China;
2.Department of Center for Reproductive Medicine, Taihe Hospital of Shiyan City, Hubei Province, Shiyan 442000, China
Abstract：Objective To study the association between -592C＞A polymorphism within gene promoter region of interleukin-10 (IL-10) and susceptibility of cervical cancer. Methods The relevant literatures about -592C＞A polymorphism within gene promoter region of IL-10 and susceptibility of cervical cancer of PubMed, Embase, Web of SCI, CNKI and Wanfang from inception to March 2018 were searched. After the data of literatures met with inclusion criteria was extracted, taking OR value and 95% confidence interval as effect indicators, STATA 14.0 software was used to make meta analysis, and the occurrence of bias, sensibility, accumulation analysis were detected. Results Ten published studies including 3149 patients with cervical cancer and 2237 normal controls were enrolled. The results of meta analysis showed that in the total population, no significant association between IL-10 -592C＞A polymorphism and susceptibility of cervical cancer was found. After that, the subgroup analysis aiming at multiple factors showed that -592C＞A polymorphism within gene promoter region of IL-10 had significant correlation with the occurrence of cervical cancer in European (P ＜ 0.05). Conclusion The changes of -592C＞A polymorphism within IL-10 gene may increase the risk of suffering from cervical cancer in European.
郭冲1 张志军2. 白细胞介素10基因启动子区-592C＞A位点多态性与宫颈癌易感性的Meta分析[J]. 中国医药导报, 2018, 15(17): 89-93,105.
GUO Chong1 ZHANG Zhijun2. Association between -592C＞A polymorphism within gene promoter region of interleukin-10 and susceptibility of cervical cancer: a meta-analysis. 中国医药导报, 2018, 15(17): 89-93,105.
[1] Torre LA，Bray F，Siegel RL，et al. Global cancer statistics，2012 [J]. CA Cancer J Clin，2015，65（2）：87-108.
[2] Smith HO，Tiffany MF，Qualls CR，et al. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States--a 24-year population-based study [J]. Gynecol Oncol，2000，78（2）：97-105.
[3] Wang SS，Sherman ME，Hildesheim A，et al. Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976-2000 [J]. Cancer，2004，100（5）：1035-1044.
[4] Nedovic J，Protrka Z，Ninkovic S，et al. Cisplatin monotherapy with concurrent radiotherapy versus combination of cisplatin and 5-fluorouracil chemotherapy with concurrent radiotherapy in patients with locoregionally advanced cervical carcinoma [J]. J BUON，2012，17（4）：740-745.
[5] Lee CH，Chang JS，Syu SH，et al. IL-1beta promotes malignant transformation and tumor aggressiveness in oral cancer [J]. J Cell Physiol，2015，230（4）：875-884.
[6] Liu H，Antony S，Roy K，et al. Interleukin-4 and interleukin-13 increase NADPH oxidase 1-related proliferation of human colon cancer cells [J]. Oncotarget，2017，8（24）：38113-38135.
[7] Cecil DL，Holt GE，Park KH，et al. Elimination of IL-10-inducing T-helper epitopes from an IGFBP-2 vaccine ensures potent antitumor activity [J]. Cancer Res，2014，74（10）：2710-2718.
[8] Howell WM，Rose-Zerilli MJ. Cytokine gene polymorphisms，cancer susceptibility，and prognosis [J]. J Nutr，2007，137（1）：194S-199S.
[9] Eskdale J，Kube D，Tesch H，et al. Mapping of the human IL10 gene and further characterization of the 5' flanking sequence [J]. Immunogenetics，1997，46（2）：120-128.
[10] Roh JW，Kim MH，Seo SS，et al. Interleukin-10 promoter polymorphisms and cervical cancer risk in Korean women [J]. Cancer Lett，2002，184（1）：57-63.
[11] Zoodsma M，Nolte IM，Schipper M，et al. Interleukin-10 and Fas polymorphisms and susceptibility for（pre）neoplastic cervical disease [J]. Int J Gynecol Cancer，2005， 15（3）：282-290.
[12] Ivansson EL，Gustavsson IM，Magnusson JJ，et al. Gyllensten UB. Variants of chemokine receptor 2 and interleukin 4 receptor， but not interleukin 10 or Fas ligand， increase risk of cervical cancer [J]. Int J Cancer，2007， 121（11）：2451-2457.
[13] 熊兴东，卢盛祥，曾俐琴，等.IL-10 -592A＞C多态与宫颈癌遗传易感的相关性分析[J].中国优生与遗传杂志，2010，18（3）：46-48.
[14] 于晓牧，马冬，吴尚青，等.IL-10基因多态性与宫颈癌相关性的研究[J].中华医院感染学杂志，2011，21（20）：239-241.
[15] Shekari M，Kordi-Tamandani DM，MalekZadeh K，et al. Effect of anti-inflammatory（IL-4，IL-10）cytokine genes in relation to risk of cervical carcinoma [J]. Am J Clin Oncol，2012，35（6）：514-519.
[16] Singhal P，Kumar A，Bharadwaj S，et al. Association of IL-10 GTC haplotype with serum level and HPV infection in the development of cervical carcinoma [J]. Tumour Biol，2015，36（4）：2287-2298.
[17] Zidi S，Gazouani E，Stayoussef M，et al. IL-10 gene promoter and intron polymorphisms as genetic biomarkers of cervical cancer susceptibility among Tunisians [J]. Cytokine，2015，76（2）：343-347.
[18] Torres-Poveda K，Burguete-Garcia AI，Bahena-Roman M，et al. Risk allelic load in Th2 and Th3 cytokines genes as biomarker of susceptibility to HPV-16 positive cervical cancer：a case control study [J]. BMC Cancer，2016，16：330.
[19] Bai CY，Shi XY，He J，et al. Association between IL-10 genetic variations and cervical cancer susceptibility in a Chinese population [J]. Genet Mol Res，2016，15（3）：42238.
[20] Liu H，Antony S，Roy K，et al. Interleukin-4 and interleukin-13 increase NADPH oxidase 1-related proliferation of human colon cancer cells [J]. Oncotarget，2017，8（24）：38113-38135.
[21] Niu YM，Du XY，Cai HX，et al. Increased risks between Interleukin-10 gene polymorphisms and haplotype and head and neck cancer: a meta-analysis [J]. Sci Rep，2015，27（5）：17149.
2018, Vol. 15 
京公网安备 11010502046598号